drugset / Trial / NCT03439514

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

NCT03439514

Phase 3 Terminated 77 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA). The study will further evaluate a dose level of study drug (ARRY-371797) that has shown preliminary efficacy and safety in this patient population. After the primary analysis has been performed, eligible patients may receive open-label treatment with ARRY-371797.

Timeline

Start
2018-04-17
Primary completion
2022-10-13
Completion
2022-10-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ARRY-371797 Small molecule 400 mg Oral